{"id":33554,"date":"2025-05-15T22:55:22","date_gmt":"2025-05-15T14:55:22","guid":{"rendered":"https:\/\/flcube.com\/?page_id=33554"},"modified":"2025-05-15T22:55:22","modified_gmt":"2025-05-15T14:55:22","slug":"apr-2025-fineline-deals-book","status":"publish","type":"page","link":"https:\/\/flcube.com\/?page_id=33554","title":{"rendered":"Apr. 2025 Fineline Deals Book"},"content":{"rendered":"\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>China Pharmaceutical BD Transaction Review &#8211; Deeply empowering pharmaceutical transactions to facilitate collaboration and jointly build a new ecosystem for BD communication. &#8211; Fineline Deals Book Apr. 2025<\/p>\n<\/blockquote>\n\n\n\n<p class=\"is-style-info\">According to incomplete statistics from Fineline Info &amp; Tech, there were a total of <strong>15<\/strong> pharmaceutical BD and M&amp;A transactions in China in Apr 2025, including 1<strong>3<\/strong> outbound China and <strong>2<\/strong> domestic Transactions.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"193\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" src=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/38-02-1024x193.png\" alt=\"Fineline Info &amp; Tech\" class=\"wp-image-13755\" srcset=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/38-02-1024x193.png 1024w, https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/38-02-300x57.png 300w, https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/38-02-768x145.png 768w, https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/38-02-610x115.png 610w, https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/38-02.png 1214w\" \/><\/figure>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/Apr.-2025-Fineline-Deals-Book-1.pdf\" type=\"application\/pdf\" style=\"width:100%;height:610px\" aria-label=\"Embed of Apr. 2025 Fineline Deals Book.\"><\/object><a id=\"wp-block-file--media-8b5c785d-76f4-47af-809f-9eeeda1f8b8a\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/Apr.-2025-Fineline-Deals-Book-1.pdf\">Apr. 2025 Fineline Deals Book<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/Apr.-2025-Fineline-Deals-Book-1.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-8b5c785d-76f4-47af-809f-9eeeda1f8b8a\">Download<\/a><\/div>\n\n\n\n<div class=\"wp-block-coblocks-features coblocks-features-115104548427\"><div class=\"wp-block-coblocks-features__inner has-1-columns has-left-content has-no-gutter\">\n<div class=\"wp-block-coblocks-feature coblocks-feature-115104548517\"><div class=\"wp-block-coblocks-feature__inner has-no-padding\">\n<h4 class=\"wp-block-heading\" id=\"h-cross-border-license-in\">Outbound China<\/h4>\n<\/div><\/div>\n<\/div><\/div>\n\n\n\n<p class=\"has-text-align-left\"><a href=\"https:\/\/flcube.com\/?p=24063\"><strong>Fosun Pharma\u2019s Henlius Completes Clinical Trial Filing for HLX301 in Australia<\/strong><\/a><\/p>\n\n\n\n<p>China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/600196:SHA\">SHA: 600196<\/a>,\u00a0<a href=\"https:\/\/www.google.com\/finance\/quote\/2196:HKG\">HKG: 2196<\/a>) announced that its subsidiary, Shanghai Henlius Biotech (<a href=\"hkg: 2696\">HKG: 2696<\/a>), has completed a clinical trial filing for HLX301 in Australia. Henlius will conduct a Phase I clinical study in the country for the bispecific antibody (BsAb) targeting programmed-death-ligand 1 (PD-L1) and T cell immunoglobulin and ITIM domains (TIGIT) in locally advanced or metastatic solid tumors&#8230;. [<a href=\"https:\/\/flcube.com\/?p=24063\">Full Artical<\/a>]<\/p>\n\n\n\n<p class=\"has-text-align-left\"><strong><a href=\"https:\/\/flcube.com\/?p=28320\"><\/a><a href=\"https:\/\/flcube.com\/?p=32508\">Shanghai Henlius and Alvogen Korea Ink Licensing Deal for HanSiZhuang (Serplulimab)<\/a><\/strong><\/p>\n\n\n\n<p>China-based Shanghai Henlius Biotech Inc., (<a href=\"https:\/\/www.google.com\/finance\/quote\/2696:HKG\">HKG: 2696<\/a>) has entered into a licensing agreement with South Korea-headquartered Alvogen Korea Co., Ltd. regarding its HanSiZhuang (serplulimab) drug&#8230;. [<a href=\"https:\/\/flcube.com\/?p=32508\">Full Artical<\/a>]<\/p>\n\n\n\n<p class=\"has-text-align-left\"><strong><a href=\"https:\/\/flcube.com\/?p=28320\"><\/a><a href=\"https:\/\/flcube.com\/?p=33171\">Shanghai Escugen Partners with ConjugateBio on EZWi-Fit Platform for ADC Development<\/a><\/strong><\/p>\n\n\n\n<p>China-based Shanghai Escugen has entered into an exclusive option agreement with US-headquartered ConjugateBio Inc. regarding its EZWi-Fit platform. This next-generation linker payload technology platform offers significant competitive advantages in safety, efficacy, drug resistance, and pharmacokinetic characteristics&#8230;. [<a href=\"https:\/\/flcube.com\/?p=33171\">Full Artical<\/a>]<\/p>\n\n\n\n<p class=\"has-text-align-left\"><strong><a href=\"https:\/\/flcube.com\/?p=32335\">QYuns Therapeutics Signs Global Licensing Deal with Caldera for Autoimmune BsAb<\/a><\/strong><\/p>\n\n\n\n<p>China-based Jiangsu QYuns Therapeutics Co., Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/2509:HKG\">HKG: 2509<\/a>) has entered into a licensing agreement with US-headquartered Caldera Therapeutics for its preclinical long-acting bispecific antibody (BsAb) QX030N, targeting autoimmune diseases. This strategic partnership underscores QYuns\u2019 commitment to advancing innovative therapies in the autoimmune space&#8230; [<a href=\"https:\/\/flcube.com\/?p=32335\">Full Artical<\/a>]<\/p>\n\n\n\n<p class=\"has-text-align-left\"><strong><a href=\"https:\/\/flcube.com\/?p=32268\">JW Therapeutics Enters Licensing Pact with Juno Therapeutics for sLVV Process<\/a><\/strong><\/p>\n\n\n\n<p>China-based JW Therapeutics (<a href=\"https:\/\/www.google.com\/finance\/quote\/2126:HKG\">HKG: 2126<\/a>), co-founded by Juno Therapeutics Inc. (a Bristol-Myers Squibb company) and WuXi AppTec in 2016, announced a technology licensing agreement with Juno. Upon approval from independent shareholders, JW Therapeutics will grant Juno a nonexclusive license to its JW sLVV production process and related technical knowledge. In return, Juno will pay JW Therapeutics up to USD 10 million&#8230;. [<a href=\"https:\/\/flcube.com\/?p=32268\">Full Artical<\/a>]<\/p>\n\n\n\n<p class=\"has-text-align-left\"><strong><a href=\"https:\/\/flcube.com\/?p=32055\">Velavigo and Ollin Biosciences Ink licensing Deal for First-in-Class BsAb VBS-102<\/a><\/strong><\/p>\n\n\n\n<p>Velavigo, a biotech company with operations in Shanghai, China, and Boston, USA, has entered into a licensing agreement with Ollin Biosciences, Inc. This strategic partnership grants Ollin exclusive development, manufacturing, and commercialization rights to Velavigo\u2019s VBS-102, a first-in-class bispecific antibody (BsAb), on a global scale excluding Greater China. Velavigo will retain rights for Greater China&#8230;. [<a href=\"https:\/\/flcube.com\/?p=32055\">Full Artical<\/a>]<\/p>\n\n\n\n<p class=\"has-text-align-left\"><strong><a href=\"https:\/\/flcube.com\/?p=32065\">Sanofi Licenses First-in-Class BsAbs from Earendil Labs for Autoimmune and IBD Treatment<\/a><\/strong><\/p>\n\n\n\n<p>French pharmaceutical giant Sanofi (<a href=\"https:\/\/www.google.com\/finance\/quote\/SAN:EPA\">EPA: SAN<\/a>,\u00a0<a href=\"https:\/\/www.google.com\/finance\/quote\/SNY:NASDAQ\">NASDAQ: SNY<\/a>) has entered into a licensing agreement with US-based Earendil Labs to acquire exclusive worldwide rights to two first-in-class bispecific antibodies (BsAbs) targeting autoimmune and inflammatory bowel diseases (IBD). This strategic move underscores Sanofi\u2019s commitment to expanding its portfolio in these therapeutic areas&#8230;. [<a href=\"https:\/\/flcube.com\/?p=32065\">Full Artical<\/a>]<\/p>\n\n\n\n<p class=\"has-text-align-left\"><strong><a href=\"https:\/\/flcube.com\/?p=31965\">Zhaoke Ophthalmology Signs Distribution Agreements with Thailand\u2019s Interpharma for Myopia and Presbyopia Treatments<\/a><\/strong><\/p>\n\n\n\n<p>China-based Zhaoke Ophthalmology Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/6622:HKG\">HKG: 6622<\/a>) has announced the signing of three distribution and supply agreements with Thailand\u2019s Interpharma Public Company Limited. The agreements cover NVK002, a topical ophthalmic atropine solution for pediatric myopia progression; Brimochol PF, a presbyopia treatment; and six generic glaucoma medications, including bimatoprost, bimatoprost timolol, latanoprost, latanoprost timolol, travoprost, and travoprost timolol&#8230;. [<a href=\"https:\/\/flcube.com\/?p=31965\">Full Artical<\/a>]<\/p>\n\n\n\n<p class=\"has-text-align-left\"><strong><a href=\"https:\/\/flcube.com\/?p=31677\">Zhaoke Ophthalmology Launches Phase II Study for Brimochol PF in Presbyopia Treatment<\/a><\/strong><\/p>\n\n\n\n<p>Zhaoke Ophthalmology Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/6622:HKG\">HKG: 6622<\/a>) has announced the initiation of a multi-center, double-blinded, crossover, placebo-controlled Phase II study to evaluate the efficacy and safety of its Brimochol PF in Chinese patients with presbyopia. The study, which has completed its first patient enrollment, is expected to enroll 119 patients across 14 centers, marking a significant step in the development of this novel therapy&#8230;. [<a href=\"https:\/\/flcube.com\/?p=31677\">Full Artical<\/a>]<\/p>\n\n\n\n<p class=\"has-text-align-left\"><strong><a href=\"https:\/\/flcube.com\/?p=31467\">HuidaGene\u2019s hfCas12Max Licensed to Vita Therapeutics for Neuromuscular Cell Therapy<\/a><\/strong><\/p>\n\n\n\n<p>Shanghai-based genome medicines specialist HuidaGene Therapeutics has sublicensed its hfCas12Max platform to Vita Therapeutics, Inc., through Synthego Corporation, marking a significant expansion into new therapeutic territories. The agreement allows Vita to utilize HuidaGene\u2019s high-fidelity CRISPR-Cas12 technology in developing cell therapies for neuromuscular disorders&#8230;. [<a href=\"https:\/\/flcube.com\/?p=31467\">Full Artical<\/a>]<\/p>\n\n\n\n<p class=\"has-text-align-left\"><strong><a href=\"https:\/\/flcube.com\/?p=31349\">Hengrui Pharmaceuticals Licenses SHR7280 to Merck for Assisted Reproduction<\/a><\/strong><\/p>\n\n\n\n<p>China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (<a href=\"https:\/\/www.google.com\/finance\/quote\/600276:SHA\">SHA: 600276<\/a>) has entered into a licensing agreement with German pharmaceutical giant Merck KGaA (<a href=\"https:\/\/www.google.com\/finance\/quote\/MRK:ETR\">ETR: MRK<\/a>) for its oral non-peptide GnRH receptor antagonist, SHR7280. This collaboration focuses on advancing SHR7280 in the field of assisted reproduction, with Merck securing exclusive commercialization rights in mainland China&#8230;. [<a href=\"https:\/\/flcube.com\/?p=31349\">Full Artical<\/a>]<\/p>\n\n\n\n<p class=\"has-text-align-left\"><strong><a href=\"https:\/\/flcube.com\/?p=31020\">Abbisko Therapeutics Secures $85M from Merck for Pimicotinib Global Rights<\/a><\/strong><\/p>\n\n\n\n<p>Shanghai-based biotech Abbisko Therapeutics Co., Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/2256:HKG\">HKG: 2256<\/a>) announced that its German partner Merck KGaA (<a href=\"https:\/\/www.google.com\/finance\/quote\/MRK:ETR\">ETR: MRK<\/a>) has exercised the global commercialization option for pimicotinib (ABSK021). This move triggers an option exercise fee of USD 85.0 million, as per the agreement signed in December 2023&#8230;. [<a href=\"https:\/\/flcube.com\/?p=31020\">Full Artical<\/a>]<\/p>\n\n\n\n<p class=\"has-text-align-left\"><strong><a href=\"https:\/\/flcube.com\/?p=31143\">Organon Acquires U.S. Rights to TOFIDENCE from Biogen<\/a><\/strong><\/p>\n\n\n\n<p>Organon (<a href=\"https:\/\/www.google.com\/finance\/quote\/OGN:NYSE\">NYSE: OGN<\/a>) announced today that it has acquired regulatory and commercial rights in the U.S. for TOFIDENCE, a biosimilar to ACTEMRA, from Biogen Inc. (<a href=\"https:\/\/www.google.com\/finance\/quote\/BIIB:NASDAQ\">NASDAQ: BIIB<\/a>). This acquisition follows an agreement where Bio-Thera Solutions Ltd., the developer of TOFIDENCE, granted Biogen exclusive rights to the product in global markets excluding China in April 2021&#8230;. [<a href=\"https:\/\/flcube.com\/?p=31143\">Full Artical<\/a>]<\/p>\n\n\n\n<div class=\"wp-block-coblocks-features coblocks-features-115104548427\"><div class=\"wp-block-coblocks-features__inner has-1-columns has-left-content has-no-gutter\">\n<div class=\"wp-block-coblocks-feature coblocks-feature-115104548517\"><div class=\"wp-block-coblocks-feature__inner has-no-padding\">\n<h4 class=\"wp-block-heading\" id=\"h-cross-border-license-out\">Dometsic Transactions in China<\/h4>\n<\/div><\/div>\n<\/div><\/div>\n\n\n\n<p><a href=\"https:\/\/flcube.com\/?p=20433\"><\/a><strong><a href=\"https:\/\/flcube.com\/?p=25864\"><\/a><a href=\"https:\/\/flcube.com\/?p=29236\"><\/a><a href=\"https:\/\/flcube.com\/?p=32499\">Zhejiang Jolly Pharma Invests in Lingyi Biotech for Gene Therapy Development<\/a><\/strong><\/p>\n\n\n\n<p>China-based Zhejiang Jolly Pharmaceutical Co., Ltd. (<a href=\"https:\/\/www.google.com\/finance\/quote\/300181:SHE\">SHE: 300181<\/a>) announced an investment of RMB 20 million (USD 2.7 million) in Lingyi Biotech Co., Ltd., a domestic gene therapy specialist. Additionally, Jolly Pharma has secured priority rights to obtain the distribution rights or sales agency rights for Lingyi Bio\u2019s LY-N001, a drug for Parkinson\u2019s disease (PD), in mainland China&#8230;. [<a href=\"https:\/\/flcube.com\/?p=32499\">Full Artical<\/a>]<\/p>\n\n\n\n<p><a href=\"https:\/\/flcube.com\/?p=20440\"><\/a><strong><a href=\"https:\/\/flcube.com\/?p=29236\"><\/a><strong><a href=\"https:\/\/flcube.com\/?p=29236\"><\/a><a href=\"https:\/\/flcube.com\/?p=30175\">Baheal Partners with Jiluntai for Commercialization of Technetium-99m-labeled Imaging Agent<\/a><\/strong><\/strong><\/p>\n\n\n\n<p>China-based health services and distribution giant Baheal Pharmaceutical Group (<a href=\"https:\/\/www.google.com\/finance\/quote\/301015:SHE\">SHE: 301015<\/a>) has entered into a commercialization partnership with Beijing Jiluntai Pharmaceutical Co., Ltd (Radio technology). Under the agreement, Baheal secures the rights to commercialize Jiluntai\u2019s Category 1 nuclear pharmaceutical drug, Technetium-99m-labeled hydrazinylnicotinamide-polyethylene glycol-bicyclic RGD peptide, in mainland China&#8230;.[<a href=\"https:\/\/flcube.com\/?p=32349\">Full Artical<\/a>]<\/p>\n\n\n\n<p><em>For more insights, follow <a href=\"https:\/\/flcube.com\">Fineline Info &amp; Tech<\/a><\/em><\/p>\n\n\n\n<p><strong>Previous Recommendations<\/strong><a href=\"https:\/\/flcube.com\/?page_id=21585\"><\/a><\/p>\n\n\n\n<p><a href=\"https:\/\/flcube.com\/?page_id=31747\">Mar. 2025 Fineline Deals Book<\/a><\/p>\n\n\n\n<p><a href=\"https:\/\/flcube.com\/?page_id=29292\">Feb. 2025 Fineline Deals Book<\/a><\/p>\n\n\n\n<p><a href=\"https:\/\/flcube.com\/?page_id=28350\">Jan. 2025 Fineline Deals Book<\/a><\/p>\n\n\n\n<p><a href=\"https:\/\/flcube.com\/?page_id=21585\">Dec. 2024 Fineline Deals Book<\/a><\/p>\n\n\n\n<p><a href=\"https:\/\/flcube.com\/?page_id=16824\">Nov. 2024 Fineline Deals Book<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China Pharmaceutical BD Transaction Review &#8211; Deeply empowering pharmaceutical transactions to facilitate collaboration and jointly&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","footnotes":""},"class_list":["post-33554","page","type-page","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Apr. 2025 Fineline Deals Book - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China Pharmaceutical BD Transaction Review - Deeply empowering pharmaceutical transactions to facilitate collaboration and jointly build a new ecosystem for BD communication. - Fineline Deals Book Apr. 2025\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?page_id=33554\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Apr. 2025 Fineline Deals Book\" \/>\n<meta property=\"og:description\" content=\"China Pharmaceutical BD Transaction Review - Deeply empowering pharmaceutical transactions to facilitate collaboration and jointly build a new ecosystem for BD communication. - Fineline Deals Book Apr. 2025\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?page_id=33554\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/38-02.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1214\" \/>\n\t<meta property=\"og:image:height\" content=\"229\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?page_id=33554\",\"url\":\"https:\\\/\\\/flcube.com\\\/?page_id=33554\",\"name\":\"Apr. 2025 Fineline Deals Book - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?page_id=33554#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?page_id=33554#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/38-02-1024x193.png\",\"datePublished\":\"2025-05-15T14:55:22+00:00\",\"description\":\"China Pharmaceutical BD Transaction Review - Deeply empowering pharmaceutical transactions to facilitate collaboration and jointly build a new ecosystem for BD communication. - Fineline Deals Book Apr. 2025\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?page_id=33554#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?page_id=33554\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?page_id=33554#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/38-02.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/38-02.png\",\"width\":1214,\"height\":229,\"caption\":\"Fineline Info & Tech\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?page_id=33554#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Apr. 2025 Fineline Deals Book\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Apr. 2025 Fineline Deals Book - Insight, China&#039;s Pharmaceutical Industry","description":"China Pharmaceutical BD Transaction Review - Deeply empowering pharmaceutical transactions to facilitate collaboration and jointly build a new ecosystem for BD communication. - Fineline Deals Book Apr. 2025","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?page_id=33554","og_locale":"en_US","og_type":"article","og_title":"Apr. 2025 Fineline Deals Book","og_description":"China Pharmaceutical BD Transaction Review - Deeply empowering pharmaceutical transactions to facilitate collaboration and jointly build a new ecosystem for BD communication. - Fineline Deals Book Apr. 2025","og_url":"https:\/\/flcube.com\/?page_id=33554","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","og_image":[{"width":1214,"height":229,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/38-02.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/flcube.com\/?page_id=33554","url":"https:\/\/flcube.com\/?page_id=33554","name":"Apr. 2025 Fineline Deals Book - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?page_id=33554#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?page_id=33554#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/38-02-1024x193.png","datePublished":"2025-05-15T14:55:22+00:00","description":"China Pharmaceutical BD Transaction Review - Deeply empowering pharmaceutical transactions to facilitate collaboration and jointly build a new ecosystem for BD communication. - Fineline Deals Book Apr. 2025","breadcrumb":{"@id":"https:\/\/flcube.com\/?page_id=33554#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?page_id=33554"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?page_id=33554#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/38-02.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/38-02.png","width":1214,"height":229,"caption":"Fineline Info & Tech"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?page_id=33554#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Apr. 2025 Fineline Deals Book"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]}]}},"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/pages\/33554","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=33554"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/pages\/33554\/revisions"}],"predecessor-version":[{"id":33561,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/pages\/33554\/revisions\/33561"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=33554"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}